Your session is about to expire
← Back to Search
Adalimumab for Mucopolysaccharidosis
Study Summary
This trial is studying how well adalimumab works compared to placebo in treating patients with MPS I, II, or VI.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had a stem cell transplant less than 2 years ago.I have an active or chronic Hepatitis B infection.I will not be exposed to live vaccines during the study.I have tested positive for TB or been recently exposed to it.I have a condition like multiple sclerosis or Guillain-Barre syndrome.I have had a serious infection like TB or a fungal infection.I have not been on immune suppression therapy in the last year.I weigh at least 15 kilograms.I have or had lymphoma or another type of cancer.You have problems with your blood, like having low levels of different types of blood cells or a condition called aplastic anemia.I experience more pain than most people do.I have been diagnosed with MPS I, II, or VI.You are allergic to latex.My heart's pumping ability is below normal.I have (or have not) been on enzyme replacement therapy for at least a year.I am 5 years old or older.I have 3 or more joints with limited movement.You have a condition called active graft versus host disease.You have a known or suspected allergy to adalimumab or similar products.I do not have any active infections.
- Group 1: Adalimumab
- Group 2: Open-label adalimumab
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do we have previous data to suggest that Adalimumab Injection [Humira] is effective?
"Currently, there are 51 ongoing clinical trials studying the effects of Adalimumab Injection [Humira]. Of these active studies, 14 are in Phase 3. The majority of research locations for Adalimumab Injection [Humira] are based in London, but there are a total of 2044 medical centres running trials for this medication worldwide."
How many total subjects are included in the research?
"The listing on clinicaltrials.gov says that the research team is still recruiting patients for this study. The trial was originally posted on 6/5/2017, and the most recent update was 8/9/2022. They are looking to enroll 14 individuals at 2 different sites."
Are there any available spots for volunteers in this research project?
"This trial, which can be found on clinicaltrials.gov, is still looking for participants. The original posting was on June 5th, 2017 and the most recent update was on August 9th, 2022."
What conditions does Adalimumab Injection [Humira] help ameliorate?
"Most frequently, Adalimumab Injection [Humira] is given to patients suffering from ankylosing spondylitis. That said, this medication can also be used as treatment for rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis."
Share this study with friends
Copy Link
Messenger